5-Fluorouracil: Molecular mechanisms of cell death

Apoptosis, Cell Signaling, and Human Diseases

Volumn 1, Issue , 2007, Pages 263-278

  Longley, Daniel B ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

5 Fluorouracil; apoptosis; Bcl 2; death receptors; growth factor receptors

Indexed keywords

EID: 76649129143     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-200-7_11     Document Type: Chapter

References (131)

1. IMPACT, Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345(8955): 939-944.
2. Johnston PG, Kaye S. Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 2001;12(8):639-646.
3. Giacchetti S, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18(1):136-147.
4. Douillard JY, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355(9209):1041-1047.
5. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16(4):215-237.
6. Sommer H, Santi DV. Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2'-deoxyuridylate and methylenetetrahydrofolate. Biochem Biophys Res Commun 1974;57(3):689-695.
7. Santi DV, McHenry CD, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974;13(3):471-481.
8. Jackson RC, Grindley GB. The biochemical basis for methotrexate cytotoxicity. In: Biochemistry, Molecular Actions, and Synthetic Design. Sirotnak FM, et al., eds. New York, Academic, 1984:289-315.
9. Houghton JA, Tillman DM, Harwood FG Ratio of 2'-deoxyadenosine-5'- triphosphate/thymidine-5'-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res 1995;1(7):723-730.
10. Yoshioka A, et al. Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem 1987;262(17):8235-8241.
11. Aherne GW, et al. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifo-late (CB30900) in L1210 mouse leukaemia cells. Biochem Pharmacol 1996;51(10): 1293-1301.
12. Lindahl T. An N-glycosidase from Escherichia coli that releases free uracil from DNA containing deaminated cytosine residues. Proc Natl Acad Sci USA 1974;71(9):3649-3653.
13. Ladner RD. The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr Protein Pept Sci 2001;2(4):361-370.
14. Webley SD, et al. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331. Br J Cancer 2000;83(6):792-799.
15. Pugacheva EN, et al. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 2002;21(30): 4595-4600.
16. Webley SD, et al. The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition. Br J Cancer 2001;85(3):446-452.
17. Kufe DW, Major PP. 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem 1981;256(19):9802-9805.
18. Glazer RI, Lloyd LS. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol 1982;21(2):468-473.
19. Kanamaru R, et al. The inhibitory effects of 5-fluorouracil on the metabolism of preriboso-mal and ribosomal RNA in L-1210 cells in vitro. Cancer Chemother Pharmacol 1986;17(1): 43-46.
20. Ghoshal K, Jacob ST. Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res 1994;54(3):632-636.
21. Santi DV, Hardy LW. Catalytic mechanism and inhibition of tRNA (uracil-5-)methyltrans-ferase: evidence for covalent catalysis. Biochemistry 1987;26(26):8599-8606.
22. Randerath K, et al. Specific effects of 5-fluoropyrimidines and 5-azapyrimidines on modification of the 5 position of pyrimidines, in particular the synthesis of 5-methyluracil and 5-methylcytosine in nucleic acids. Recent Results Cancer Res 1983;84:283-297.
23. Patton JR. Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine. Biochemistry 1993;32(34):8939- 8944.
24. Doong SL, Dolnick BJ. 5-Fluorouracil substitution alters pre-mRNA splicing in vitro. J Biol Chem 1988;263(9):4467-4673.
25. Samuelsson T. Interactions of transfer RNA pseudouridine synthases with RNAs substituted with fluorouracil. Nucleic Acids Res 1991;19(22):6139-6144.
26. Takebe N, et al. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther 2001;8(12): 966-973.
27. Salonga D, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6(4):1322-1327.
28. Schwartz PM, et al. Role of uridine phosphorylase in the anabolism of 5-fluorouracil. Biochem Pharmacol 1985;34(19):3585-3589.
29. Houghton JA, Houghton PJ. Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma. Eur J Cancer Clin Oncol 1983;19(6): 807-815.
30. Evrard A, et al. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 1999;80(11):1726-1733.
31. Peters GJ, Kohne CH. Fluoropyrimidines as antifolate drugs. Antifolate drugs in cancer therapy, ed. A.L. Jackman. 1999: Humana Press, 101-145.
32. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3(5):330-338.
33. Johnston PG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55(7):1407-1412.
34. Lenz HJ, et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 1998;4(5):1243-1250.
35. Marsh S, McLeod HL. Thymidylate synthase pharmacogenomics in colorectal cancer. Clinical Colorectal Cancer 2001;1:175-178.
36. Chu E, et al. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol 1993;43(4):527-533.
37. Swain SM, et al. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7(7):890-899.
38. Chu E, et al. Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells. Mol Cell Biol 1994;14(1):207-213.
39. Longley DB, et al. Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS-and non-TS-targeted chemotherapies. Clin Cancer Res 2001;7(11):3533-3539.
40. Longley DB, et al. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 2002; 62(9):2644-2649.
41. Meyers M, et al. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001;61(13):5193-5201.
42. Elsaleh H, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001;7(5):1343-1349.
43. Banerjea A, et al. Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer 2004;3(1):21.
44. Mori S, Ogata Y, Shirouzu K. Biological features of sporadic colorectal carcinoma with high-frequency microsatellite instability: special reference to tumor proliferation and apoptosis. Int J Clin Oncol 2004;9(4):322-329.
45. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408(6810):307-310.
46. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88(3):323-331.
47. Ljungman M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2000;2(3):208-225.
48. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000; 1471(1): M43-M56.
49. Zhan Q, et al. Tumor suppressor p53 can participate in transcriptional induction of the GADD45 promoter in the absence of direct DNA binding. Mol Cell Biol 1998;18(5): 2768-2778.
50. Miyashita T, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9(6):1799-1805.
51. Petak I, Tillman DM, Houghton JA. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res 2000;6(11):4432-4341.
52. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001;29(Pt 6):684-688.
53. Yu J, et al. Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 1999;96(25):14, 517-14, 522.
54. Bunz F, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104(3):263-269.
55. Liang JT, et al. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer 2002;97(4):451-457.
56. Ahnen DJ, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998;58(6):1149-1158.
57. Paradiso A, et al. Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000;82(3):560-567.
58. Sjogren S, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88(3-4):173-182.
59. van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000;6(6):2138-2145.
60. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407(6805):770- 776.
61. Reed JC. Bcl-2 family proteins. Oncogene 1998;17(25):3225-3236.
62. Nita ME, et al. Bcl-X(L) antisense sensitizes human colon cancer cell line to 5-fluoro-uracil. Jpn J Cancer Res 2000;91(8):825-832.
63. Yang JH, et al. Chemosensitization of breast carcinoma cells with the use of bcl-2 anti-sense oligodeoxynucleotide. Breast 2004;13(3):227-231.
64. Kim R, et al. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma. Int J Mol Med 2003;11(6):799-804.
65. Xu ZW, et al. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother Pharmacol 2002;49(6): 504-510.
66. Zhang L, et al. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290(5493):989-992.
67. Violette S, et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 2002;98(4):498-504.
68. Sax JK, et al. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 2002; 4(11):842-849.
69. Miao J, et al. Bid sensitizes apoptosis induced by chemotherapeutic drugs in hepatocellular carcinoma. Int J Oncol 2004;25(3):651-659.
70. Herbst RS, Frankel SR. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 2004;10(12 Pt 2):4245s-4248s.
71. Colleoni M, et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 1999;35(4):574-579.
72. Bottini A, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000; 6(7):2751-2758.
73. Paradiso A, et al. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer 2001;84(5):651-658.
74. Sjostrom J, et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 2002;8(3):811-816.
75. Houghton JA, Harwood FG, Tillman DM. Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc Natl Acad Sci USA 1997;94(15):8144-8149.
76. Longley DB, et al. The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. Clin Cancer Res 2004;10(10):3562-3571.
77. Fan QL, et al. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Cancer Chemother Pharmacol, 2004.
78. Wu XX, Ogawa O, Kakehi Y. TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm 2004;67:365-383.
79. Timmer T, de Vries EG, de Jong S. Fas receptor-mediated apoptosis: a clinical application? J Pathol 2002;196(2):125-134.
80. Ichikawa K, et al. A novel murine anti-human Fas mAb which mitigates lymphadeno-pathy without hepatotoxicity. Int Immunol 2000;12(4):555-562.
81. Backus HH, et al. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann Oncol 2001;12(2):209-216.
82. Mottolese M, et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000;89(2):127-132.
83. von Reyher U, et al. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 1998;58(3):526-534.
84. Niehans GA, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997;57(6): 1007-1012.
85. Gratas C, et al. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 1998;58(10):2057-2062.
86. O'Connell J, et al. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack. Dis Esophagus 1999;12(2):83-89.
87. Botti C, et al. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 2004;10(4):1360-1365.
88. Bezulier K, et al. Fas/FasL expression in tumor biopsies: a prognostic response factor to fluoropyrimidines? J Clin Pharm Ther 2003;28(5):403-408.
89. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor super-family. Nat Rev Cancer 2002;2(6):420-430.
90. Wang S, El-Deiry WS. Inducible silencing of KILLER/DR5 in vivo promotes biolumines-cent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 2004;64(18):6666-6672.
91. Shimoyama S, et al. Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. Int J Oncol 2002; 21(3):643-648.
92. Mizutani Y, et al. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 2002;38 (1):167-176.
93. von Haefen C, et al. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 2004;23(50):8320-8332.
94. Naka T, et al. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002;62(20):5800-5806.
95. Krueger A, et al. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001;21(24):8247-8254.
96. Srinivasula SM, et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 1997;272(30):18, 542-18, 545.
97. Irmler M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388(6638):190-195.
98. Hu S, et al. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1-and CD-95-induced apoptosis. J Biol Chem 1997;272(28):17, 255-17, 257.
99. Ganten TM, et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004;11 Suppl 1:S86-S96.
100. Longley DB, et al. c-FLIP inhibits chemothrapy-induced colorectal cancer cell death. Oncogene 2006;25(6):838-848.
101. Ryu BK, et al. Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 2001;194(1):15-19.
102. Zhou XD, et al. Overexpression of cellular FLICE-inhibitory protein (FLIP) in gastric adenocarcinoma. Clin Sci (Lond) 2004;106(4):397-405.
103. Mild G, et al. DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Int J Cancer 2002;102(3):254-257.
104. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411(6835): 355-365.
105. Jorissen RN, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284(1):31-53.
106. Olayioye MA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 2000;19(13):3159-3167.
107. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59(2 Suppl):21-26.
108. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4(5):361-370.
109. Ross JS, et al. HER-2/neu testing in breast cancer. Am J Clin Pathol 2003;120 Suppl:S53-S71.
110. Cunningham D, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinote-can-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-345.
111. Ciardiello F, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6(5):2053-2063.
112. Koizumi F, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefi-tinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004;108(3):464-472.
113. Magne N, et al. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002;86(5):819-827.
114. Sirotnak FM, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6(12):4885-4892.
115. Van Schaeybroeck S, et al. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 2005;11(20):7480-7489.
116. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4(2):97-105.
117. Bromberg JF, et al. Stat3 as an oncogene. Cell, 1999;98(3):295-303.
118. Niu G, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002;21(46):7001-7010.
119. Horita M, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000;191(6):977-984.
120. Grandis JR, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000;97(8):4227-4232.
121. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000;96(6):2269-2276.
122. Zamo A, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002;21(7):1038-1047.
123. Real PJ, et al. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002;21(50):7611-7618.
124. Masuda M, et al. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 2002;93(3):329-339.
125. Lin A, Karin M. NF-kappaB in cancer: a marked target. Semin Cancer Biol 2003; 13(2): 107-114.
126. Karin M, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2(4):301-310.
127. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;107(3):241-246.
128. Chuang SE, et al. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 2002;63(9):1709-1716.
129. Abdel-Latif MM, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004;239(4):491-500.
130. Cusack JC. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 2003;29 Suppl 1:21-31.
131. Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003;29 Suppl 1:33-39.